

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International patent classification<sup>7</sup>:</b>  C12N 15/49, C07K 14/16, A61K 39/21, G01N 33/68	<b>A1</b>	<b>(11) International publication number:</b> WO 00/08167  <b>(43) International publication date:</b>  17 February 2000 (17.02.00)
<b>(21) International application number:</b> PCT/FR99/01871  <b>(22) International filing date:</b> 29 July 1999 (29.07.99)  <b>(30) Data relating to the priority:</b> 98/10,027 31 July 1998 (31.07.98) FR  <b>(71) Applicant (for all designated States except US):</b> PASTEUR MERIEUX SERUMS ET VACCINS [FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (US only):</b> CHEVALIER, Michel [FR/FR]; 19, rue de la Guillotière, F-38270 Beaurepaire (FR).  <b>(74) Representative:</b> GROS, Florent; Pasteur Mérieux Sérums & Vaccins, 58, avenue Leclerc, F-69007 Lyon (FR).		<b>(81) Designated states:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europeaan Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> With the International Search Report.

As printed

(54) Title: TRIMER OF HIV ENV GENE EXPRESSION PRODUCT

(54) Titre: TRIMERE DU PRODUIT D'EXPRESSION DU GENE ENV DE HIV

(57) Abstract

The invention concerns a purified recombinant glycoprotein having the following properties: a) an adherence capacity to CD4; b) an affinity with a anti-gp120 antibody capable of neutralising *in vitro* HIV cell infection; c) an affinity with an anti-gp41 antibody; d) a trimeric form free from inter-chain disulphide bonds. The invention also concerns a vaccine comprising said purified glycoprotein and an adjuvant. The invention further concerns a method for obtaining said glycoprotein as per Claim 1, which consists in expressing, by means of genetic recombining techniques, a glycoprotein corresponding to the properties a), b) and c) mentioned in Claim 1; purifying it, and subjecting it to steps involving at least a reducing agent, an ionic detergent and/or a neutral detergent in conditions leading to a glycoprotein having said properties.

(57) Abrégé

Glycoprotéine recombinante purifiée répondant aux propriétés suivantes: a) une capacité d'adhésion au CD4; b) une affinité avec un anticorps anti-gp120 capable de neutraliser *in vitro* l'infection de cellules par HIV; c) une affinité avec un anticorps anti-gp41; d) une forme trimérique dépourvue de ponts disulfures inter-chaînes. Vaccin comprenant la glycoprotéine purifiée selon l'invention et un adjuvant. Procédé d'obtention d'une glycoprotéine selon la revendication 1, dans lequel on exprime, au moyen de techniques de recombinaison génétique, une glycoprotéine répondant aux propriétés a), b) et c) énoncées à la revendication 1, on la purifie, et on la soumet à des étapes impliquant au moins un agent réducteur, un détergent ionique et/ou un détergent neutre dans des conditions telles que l'on obtient une glycoprotéine besoins de l'invention.

# **ONLY FOR INFORMATION**

Codes used to identify the PCT member States on the flyleaves of the brochures in which international applications made under the PCT are published.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia-Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	Former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Vietnam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Ivory Coast	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						